Becton Dickinson and (BDX) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Becton Dickinson and (NYSE:BDX) from a buy rating to a hold rating in a research report sent to investors on Friday, January 12th.

According to Zacks, “In the last year, Becton, Dickinson and Company, popularly known as BD, has outperformed the broader industry. BD recently completed the acquisition of C. R. Bard. The company will establish a new segment — BD Interventional in which Bard will be integrated. The acquisition is viewed as a strategic one which will generate benefits from complementary businesses and geographical expansion. In recent past, BD announced that it will divest its soft tissue core needle biopsy products for $100 million to Merit Medical. On the flip side, lackluster performance by the Medical segment, from the prior year period is a concern. Performance in the segment was affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the United States. BD temporarily paused shipments of its insulin infusion sets. The voluntary recall of Barricor blood collection tubes in the recent past also adds to our woes.”

BDX has been the topic of a number of other reports. Royal Bank of Canada reissued a hold rating and set a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Citigroup raised shares of Becton Dickinson and from a sell rating to a neutral rating in a research report on Friday, January 5th. Wells Fargo & Co assumed coverage on shares of Becton Dickinson and in a research note on Friday, September 22nd. They issued an outperform rating and a $225.00 price target for the company. Stifel Nicolaus restated a buy rating and issued a $245.00 price target on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Evercore ISI assumed coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They issued an outperform rating and a $245.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and presently has an average rating of Buy and a consensus target price of $233.80.

Becton Dickinson and (NYSE BDX) traded up $2.39 during trading on Friday, reaching $234.51. 1,466,871 shares of the company were exchanged, compared to its average volume of 1,380,000. The stock has a market capitalization of $53,800.00, a P/E ratio of 50.43, a price-to-earnings-growth ratio of 1.77 and a beta of 1.07. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton Dickinson and has a 52-week low of $169.19 and a 52-week high of $234.70.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. Becton Dickinson and’s revenue was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.12 earnings per share. analysts anticipate that Becton Dickinson and will post 10.66 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were given a dividend of $0.75 per share. The ex-dividend date was Thursday, December 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.28%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio is currently 64.52%.

Institutional investors have recently added to or reduced their stakes in the company. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in Becton Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the period. Harfst & Associates Inc. lifted its holdings in Becton Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the period. Harvest Fund Management Co. Ltd lifted its holdings in Becton Dickinson and by 82.8% in the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares during the period. Acrospire Investment Management LLC lifted its holdings in Becton Dickinson and by 259.7% in the second quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock worth $162,000 after purchasing an additional 600 shares during the period. Finally, Valeo Financial Advisors LLC acquired a new stake in Becton Dickinson and in the third quarter worth about $191,000. Institutional investors and hedge funds own 75.54% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://ledgergazette.com/2018/01/21/becton-dickinson-and-bdx-lowered-to-hold-at-zacks-investment-research.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply